Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.
Min Yan(Shanxi Agricultural University), Yajing Feng(Zhengzhou University), Xinlan Liu(Ningxia Medical University), Yuhua Song(Changchun University of Science and Technology), Huimin Lv(Zhengzhou University), Cuizhi Geng(Hebei Medical University), Shusen Wang(Sun Yat-sen University), Mengwei Zhang(Jiangnan University), Zhenzhen Liu(Zhengzhou University), Limin Niu(Zhengzhou University)
Cited by 7
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|477